Cambridge, UK-based Crescendo Biologics has appointed Theodora Harold as its new chief financial officer.
Harold brings 20 years of pharmaceutical and corporate finance industry experience to the role, with particular expertise in growing and early stage biotech companies.
She joins from PsiOxus Therapeutics where she served as chief financial officer, and has also held a number of positions at Cytomyx Holdings, OrthoMimetics, and Mission Therapeutics.
Dr Peter Pack, chief executive officer of Crescendo Biologics, said: “Theo’s appointment as Crescendo’s new chief financial officer places us in an excellent position to drive ahead with our ambitious plans to create a high value pipeline of differentiated Humabody therapeutics for treating cancer indications with substantial unmet need.
“The experience that she brings to Crescendo strengthens the existing management team and is crucial in allowing us to continue building both strategic and financial value in the company.”